Write in a clean editor, then format for Biology of Blood and Marrow Transplantation in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Biology of Blood and Marrow Transplantation is a peer-reviewed journal published by Elsevier, covering Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Biology of Blood and Marrow Transplantation 12 (2023) 45–58.
Formats any DOI in Biology of Blood and Marrow Transplantation style. No sign-up. |
| Publishes research in | Hematopoietic Stem Cell Transplantation Acute Lymphoblastic Leukemia research Acute Myeloid Leukemia Research Immune Cell Function and Interaction T-cell and B-cell Immunology |
| ISSN | 1083-8791 |
| h-index | 168 |
| i10-index | 4,136 |
| Total citations | 247,633 |
| Top institutions publishing here | Fred Hutch Cancer Center |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the…
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologic malignancies. Two CAR T products were recently approved in the United States and Europe for the treatment ofpatients up to age 25years with relapsed or refractory B cell acute lymphoblastic leukemia and/or adults with large B…
We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease (GVHD) after outpatient nonmyeloablative conditioning and T cell-replete bone marrow transplantation from partially HLA-mismatched (haploidentical) related donors. Patients with advanced hematologic malignancies (n = 67) or paroxysmal nocturnal hemoglobinuria (n = 1) received Cy 50 mg/kg i.v.…
Defining conditioning regimen intensity has become a critical issue for the hemopoietic stem cell transplant (HSCT) community. In the present report we propose to define conditioning regimens in 3 categories: (1) myeloablative (MA) conditioning, (2) reduced-intensity conditioning (RIC), and (3) nonmyeloablative (NMA) conditioning. Assignment to these categories is based on the duration of cytopenia and…
